Vicapsys Life Sciences, Inc. (VICP)
USD 1.77
(39.37%)
USD 1.77
(39.37%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 344.44 Thousand USD | 2543.4% |
| 2022 | -14.09 Thousand USD | 93.51% |
| 2021 | -217.29 Thousand USD | -17023.33% |
| 2020 | -1269.00 USD | 99.52% |
| 2019 | -264.16 Thousand USD | -206.0% |
| 2018 | -86.33 Thousand USD | 84.23% |
| 2017 | -547.59 Thousand USD | 0.0% |
| 2009 | 2.62 Million USD | 119.94% |
| 2008 | 1.19 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q4 | 344.44 Thousand USD | 35.76% |
| 2023 Q2 | 31.83 Thousand USD | 868.84% |
| 2023 Q1 | -4140.00 USD | 70.63% |
| 2023 Q3 | 253.72 Thousand USD | 697.11% |
| 2022 Q4 | -14.09 Thousand USD | 46.22% |
| 2022 Q3 | -26.21 Thousand USD | -51.6% |
| 2022 Q1 | -101.31 Thousand USD | 53.37% |
| 2022 Q2 | -17.28 Thousand USD | 82.94% |
| 2022 FY | -14.09 Thousand USD | 93.51% |
| 2021 Q4 | -217.29 Thousand USD | -31.26% |
| 2021 FY | -217.29 Thousand USD | -17023.33% |
| 2021 Q3 | -165.54 Thousand USD | 2.97% |
| 2021 Q2 | -170.62 Thousand USD | -460.1% |
| 2021 Q1 | -30.46 Thousand USD | -2300.55% |
| 2020 Q3 | -1654.00 USD | 66.83% |
| 2020 Q4 | -1269.00 USD | 23.28% |
| 2020 Q2 | -4986.00 USD | 83.89% |
| 2020 Q1 | -30.94 Thousand USD | 88.28% |
| 2020 FY | -1269.00 USD | 99.52% |
| 2019 Q3 | -510.64 Thousand USD | 0.0% |
| 2019 FY | -264.16 Thousand USD | -206.0% |
| 2019 Q4 | -264.16 Thousand USD | 48.27% |
| 2019 Q1 | 86.33 Thousand USD | 200.0% |
| 2018 Q4 | -86.33 Thousand USD | 0.0% |
| 2018 FY | -86.33 Thousand USD | 84.23% |
| 2017 FY | -547.59 Thousand USD | 0.0% |
| 2010 Q2 | 3.68 Million USD | 56.03% |
| 2010 Q1 | 2.36 Million USD | 23459371.75% |
| 2009 Q4 | -10.08 USD | 0.0% |
| 2009 FY | 2.62 Million USD | 119.94% |
| 2008 FY | 1.19 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | 81.034% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 109.029% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 72.532% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 98.931% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 136.682% |
| Better Therapeutics, Inc. | -860 Thousand USD | 140.052% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 101.448% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -4.873% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 92.463% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 105.915% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 89.229% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 89.123% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 93.114% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 99.743% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | -92.267% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 97.208% |
| Molecular Templates, Inc. | 707 Thousand USD | 51.281% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 21.439% |
| NexImmune, Inc. | -3.13 Million USD | 110.992% |
| Orgenesis Inc. | 21.78 Million USD | 98.419% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 86.833% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 69265.863% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 107.312% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 376.497% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 99.689% |
| Statera Biopharma, Inc. | 14.41 Million USD | 97.611% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 104.535% |
| Trevena, Inc. | 2.25 Million USD | 84.746% |
| Vaxxinity, Inc. | 10.13 Million USD | 96.6% |
| Vaccinex, Inc. | -1.28 Million USD | 126.743% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 97.398% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -378.65% |